Advaxis Inc (ADXS) 14.32 $ADXS Nasdaq stocks po
Post# of 64086
Posted On: 03/16/2015 1:29:37 PM
Advaxis Inc (ADXS) 14.32 $ADXS
Nasdaq stocks posting largest percentage increases
AP - 9 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
USAP: 25.50 (+2.64), INO: 8.33 (+1.29), ADXS: 14.32 (+1.91), ICEL: 8.62 (+0.99), AFMD: 7.16 (+1.01), IPDN: 5.56 (+0.52), REPH: 6.75 (+0.80)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 44 mins ago
SCON: 1.35 (-0.22), NES: 2.51 (-0.41), ADXS: 14.32 (+1.91), PRTS: 2.20 (-0.37), PFIE: 1.46 (-0.34), MVIS: 3.16 (+0.42), NSLP: 5.25 (-1.16), TRIL: 17.45 (+1.80), VRML: 1.82 (+0.15), DSKY: 7.51 (-3.31), STRL: 3.59 (+0.59), INO: 8.33 (+1.29), ENZ: 2.78 (-0.53), ICEL: 8.62 (+0.99), MTL: 1.05 (-0.49), MSO: 6.31 (+0.75), HELI: 1.44 (-0.21), PKOH: 47.58 (-8.56), OGEN: 1.49 (+0.29), BLPH: 10.95 (+1.20)
Why Advaxis, Inc. Stock Ripped Higher Today
George Budwell, The Motley Fool - Motley Fool - 1 hr 51 mins ago
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the clinical-stage biotech Advaxis ...
ADXS: 14.32 (+1.91), MRK: 57.03 (+0.83), AZN: 68.82 (+1.47)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 8:14AM CDT
KNDI: 14.35 (+1.12), WLL: 37.65 (-2.35), ADXS: 14.32 (+1.91), LTM: 70.62 (+3.42), MVIS: 3.16 (+0.42), AMRN: 3.01 (+0.11), MTL: 1.05 (-0.49), FXCM: 2.40 (-0.18), CTIC: 1.97 (unch), DSKY: 7.51 (-3.31)
Esophageal Cancer Therapeutics Pipeline Review 2015 - 40 Companies & 57 Drug Profiles
M2 - Wed Mar 11, 7:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqnm8/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Genmab A/S - GlaxoSmithKline plc - Glycotope GmbH - Hutchison MediPharma Limited - ImmunoFrontier, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Karyopharm Therapeutics, Inc. - Mebiopharm Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Omnitura Therapeutics Inc. - Oncolys BioPharma Inc. - Ono Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2m...eal_cancer
CLRB: 2.57 (-0.06), IMMU: 4.22 (-0.04), ADXS: 14.32 (+1.91), CERU: 8.23 (+0.21), IMGN: 7.65 (-0.20), ARQL: 2.04 (-0.15), AMGN: 161.87 (+7.61), GSK: 46.89 (+0.52), BMY: 67.84 (+0.97), OMER: 24.13 (-1.08), MACK: 11.82 (+0.03), BLCM: 24.22 (+1.39), AZN: 68.82 (+1.47), AVEO: 1.28 (-0.12), NVS: 97.93 (+0.89), KPTI: 30.61 (+2.53), CELGZ: 3.02 (-0.03)
Gynecologic Oncology Group (GOG) Commences Enrollment in Stage 2 of GOG-0265 Clinical Trial
GlobeNewswire - Wed Mar 11, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the Gynecologic Oncology Group (GOG), now part of NRG Oncology, has enrolled the first patient in Stage 2 of its ongoing Phase 2 open-label clinical study of ADXS-HPV in patients with persistent or recurrent cervical cancer with documented disease progression. GOG-0265 has been amended to allow patients in Stage 2 to continue to receive repeat cycles of therapy until progression.
ADXS: 14.32 (+1.91)
Advaxis to Present at the Cowen and Company 35th Annual Health Care Conference
GlobeNewswire - Mon Mar 02, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor, President and Chief Executive Officer of Advaxis, will present at the Cowen and Company 35th Annual Health Care Conference being held March 2-4, 2015, at the Boston Marriott Copley Place in Boston, MA.
ADXS: 14.32 (+1.91)
First Week of ADXS October 16th Options Trading
StockOptionsChannel.com - Fri Feb 27, 9:44AM CST
Investors in Advaxis, Inc. saw new options become available this week, for the October 16th expiration.
ADXS: 14.32 (+1.91)
5 Stocks Insiders Love Right Now: GE, Mondelez and More
at The Street - Wed Feb 25, 6:00AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
GE: 25.37 (+0.33), ADXS: 14.32 (+1.91), MDLZ: 34.60 (+0.09), MDGN: 8.15 (-0.08), MDAS: 19.08 (+0.12)
InsiderInsights.com Daily Round Up 2/20/15: GPRO, WMS, TNGO, SONS
InsiderInsights - at Seeking Alpha - Sat Feb 21, 11:18PM CST
TNGO: 12.26 (-0.44), GPRO: 39.18 (-0.95), ADXS: 14.32 (+1.91), GE: 25.37 (+0.33), PNNT: 9.50 (-0.05), SONS: 15.92 (+0.11), WMS: 27.92 (+0.07), JOB: 1.08 (unch), BMS: 46.78 (+0.05), GOOG: 555.16 (+7.84), MAS: 26.35 (-0.11), ENT: 13.29 (+0.08), MXWL: 7.51 (+0.18), MSG: 76.90 (-1.29), TSRA: 39.78 (+0.36), CUDA: 37.38 (+0.59), THLD: 4.35 (-0.18), SIX: 46.20 (-1.40), TWTR: 46.31 (-0.35), DATA: 93.09 (+0.43)
Advaxis Surges Higher on Additional Institutional Interest
at The Street - Thu Feb 19, 8:15AM CST
Advaxis stock rallied after a private placement showed added fund participation. Read how this move has rebutted the short thesis.
ADXS: 14.32 (+1.91)
Advaxis completes $23M financing
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 12:00PM CST
ADXS: 14.32 (+1.91)
Advaxis Completes $23 Million Financing
GlobeNewswire - Wed Feb 18, 11:15AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that it has executed definitive securities purchase agreements with several institutional investors for gross proceeds of approximately $23.0 million in a registered direct offering of approximately 3.1 million shares at a price of $7.50 per share. The pricing on this transaction reflects the at-the-market closing price on February 17, 2015.
ADXS: 14.32 (+1.91)
Advaxis Appoints Mayo Pujols Vice President, Manufacturing
GlobeNewswire - Fri Feb 13, 9:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Mayo Pujols as Vice President, Manufacturing. Mr. Pujols brings to Advaxis more than 22 years of experience in global commercial and clinical manufacturing, technology transfer, and product development strategy.
ADXS: 14.32 (+1.91), MRK: 57.03 (+0.83)
Advaxis teams up with Incyte in cervical cancer
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 10:47AM CST
ADXS: 14.32 (+1.91), INCY: 90.14 (+0.83)
Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer
GlobeNewswire - Wed Feb 11, 9:55AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte Corporation (Nasdaq:INCY) to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). The Phase 2 multicenter, open-label, preoperative window-study will evaluate the safety and efficacy of ADXS-HPV as a monotherapy and in combination with epacadostat in approximately 20 patients with Stage I-IIa human papillomavirus (HPV)-associated cervical cancer.
ADXS: 14.32 (+1.91), INCY: 90.14 (+0.83)
Nasdaq stocks posting largest percentage increases
AP - 9 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
USAP: 25.50 (+2.64), INO: 8.33 (+1.29), ADXS: 14.32 (+1.91), ICEL: 8.62 (+0.99), AFMD: 7.16 (+1.01), IPDN: 5.56 (+0.52), REPH: 6.75 (+0.80)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 44 mins ago
SCON: 1.35 (-0.22), NES: 2.51 (-0.41), ADXS: 14.32 (+1.91), PRTS: 2.20 (-0.37), PFIE: 1.46 (-0.34), MVIS: 3.16 (+0.42), NSLP: 5.25 (-1.16), TRIL: 17.45 (+1.80), VRML: 1.82 (+0.15), DSKY: 7.51 (-3.31), STRL: 3.59 (+0.59), INO: 8.33 (+1.29), ENZ: 2.78 (-0.53), ICEL: 8.62 (+0.99), MTL: 1.05 (-0.49), MSO: 6.31 (+0.75), HELI: 1.44 (-0.21), PKOH: 47.58 (-8.56), OGEN: 1.49 (+0.29), BLPH: 10.95 (+1.20)
Why Advaxis, Inc. Stock Ripped Higher Today
George Budwell, The Motley Fool - Motley Fool - 1 hr 51 mins ago
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the clinical-stage biotech Advaxis ...
ADXS: 14.32 (+1.91), MRK: 57.03 (+0.83), AZN: 68.82 (+1.47)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 8:14AM CDT
KNDI: 14.35 (+1.12), WLL: 37.65 (-2.35), ADXS: 14.32 (+1.91), LTM: 70.62 (+3.42), MVIS: 3.16 (+0.42), AMRN: 3.01 (+0.11), MTL: 1.05 (-0.49), FXCM: 2.40 (-0.18), CTIC: 1.97 (unch), DSKY: 7.51 (-3.31)
Esophageal Cancer Therapeutics Pipeline Review 2015 - 40 Companies & 57 Drug Profiles
M2 - Wed Mar 11, 7:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqnm8/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Genmab A/S - GlaxoSmithKline plc - Glycotope GmbH - Hutchison MediPharma Limited - ImmunoFrontier, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Karyopharm Therapeutics, Inc. - Mebiopharm Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Omnitura Therapeutics Inc. - Oncolys BioPharma Inc. - Ono Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2m...eal_cancer
CLRB: 2.57 (-0.06), IMMU: 4.22 (-0.04), ADXS: 14.32 (+1.91), CERU: 8.23 (+0.21), IMGN: 7.65 (-0.20), ARQL: 2.04 (-0.15), AMGN: 161.87 (+7.61), GSK: 46.89 (+0.52), BMY: 67.84 (+0.97), OMER: 24.13 (-1.08), MACK: 11.82 (+0.03), BLCM: 24.22 (+1.39), AZN: 68.82 (+1.47), AVEO: 1.28 (-0.12), NVS: 97.93 (+0.89), KPTI: 30.61 (+2.53), CELGZ: 3.02 (-0.03)
Gynecologic Oncology Group (GOG) Commences Enrollment in Stage 2 of GOG-0265 Clinical Trial
GlobeNewswire - Wed Mar 11, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the Gynecologic Oncology Group (GOG), now part of NRG Oncology, has enrolled the first patient in Stage 2 of its ongoing Phase 2 open-label clinical study of ADXS-HPV in patients with persistent or recurrent cervical cancer with documented disease progression. GOG-0265 has been amended to allow patients in Stage 2 to continue to receive repeat cycles of therapy until progression.
ADXS: 14.32 (+1.91)
Advaxis to Present at the Cowen and Company 35th Annual Health Care Conference
GlobeNewswire - Mon Mar 02, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor, President and Chief Executive Officer of Advaxis, will present at the Cowen and Company 35th Annual Health Care Conference being held March 2-4, 2015, at the Boston Marriott Copley Place in Boston, MA.
ADXS: 14.32 (+1.91)
First Week of ADXS October 16th Options Trading
StockOptionsChannel.com - Fri Feb 27, 9:44AM CST
Investors in Advaxis, Inc. saw new options become available this week, for the October 16th expiration.
ADXS: 14.32 (+1.91)
5 Stocks Insiders Love Right Now: GE, Mondelez and More
at The Street - Wed Feb 25, 6:00AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
GE: 25.37 (+0.33), ADXS: 14.32 (+1.91), MDLZ: 34.60 (+0.09), MDGN: 8.15 (-0.08), MDAS: 19.08 (+0.12)
InsiderInsights.com Daily Round Up 2/20/15: GPRO, WMS, TNGO, SONS
InsiderInsights - at Seeking Alpha - Sat Feb 21, 11:18PM CST
TNGO: 12.26 (-0.44), GPRO: 39.18 (-0.95), ADXS: 14.32 (+1.91), GE: 25.37 (+0.33), PNNT: 9.50 (-0.05), SONS: 15.92 (+0.11), WMS: 27.92 (+0.07), JOB: 1.08 (unch), BMS: 46.78 (+0.05), GOOG: 555.16 (+7.84), MAS: 26.35 (-0.11), ENT: 13.29 (+0.08), MXWL: 7.51 (+0.18), MSG: 76.90 (-1.29), TSRA: 39.78 (+0.36), CUDA: 37.38 (+0.59), THLD: 4.35 (-0.18), SIX: 46.20 (-1.40), TWTR: 46.31 (-0.35), DATA: 93.09 (+0.43)
Advaxis Surges Higher on Additional Institutional Interest
at The Street - Thu Feb 19, 8:15AM CST
Advaxis stock rallied after a private placement showed added fund participation. Read how this move has rebutted the short thesis.
ADXS: 14.32 (+1.91)
Advaxis completes $23M financing
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 12:00PM CST
ADXS: 14.32 (+1.91)
Advaxis Completes $23 Million Financing
GlobeNewswire - Wed Feb 18, 11:15AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that it has executed definitive securities purchase agreements with several institutional investors for gross proceeds of approximately $23.0 million in a registered direct offering of approximately 3.1 million shares at a price of $7.50 per share. The pricing on this transaction reflects the at-the-market closing price on February 17, 2015.
ADXS: 14.32 (+1.91)
Advaxis Appoints Mayo Pujols Vice President, Manufacturing
GlobeNewswire - Fri Feb 13, 9:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Mayo Pujols as Vice President, Manufacturing. Mr. Pujols brings to Advaxis more than 22 years of experience in global commercial and clinical manufacturing, technology transfer, and product development strategy.
ADXS: 14.32 (+1.91), MRK: 57.03 (+0.83)
Advaxis teams up with Incyte in cervical cancer
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 10:47AM CST
ADXS: 14.32 (+1.91), INCY: 90.14 (+0.83)
Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer
GlobeNewswire - Wed Feb 11, 9:55AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte Corporation (Nasdaq:INCY) to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). The Phase 2 multicenter, open-label, preoperative window-study will evaluate the safety and efficacy of ADXS-HPV as a monotherapy and in combination with epacadostat in approximately 20 patients with Stage I-IIa human papillomavirus (HPV)-associated cervical cancer.
ADXS: 14.32 (+1.91), INCY: 90.14 (+0.83)
(0)
(0)Scroll down for more posts ▼